Protagonist Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Protagonist Therapeutics

25/02/2025 22:01

Protagonist Therapeutics Inc PTGX.OQ reported quarterly adjusted earnings of $1.98​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of 44 cents.  The mean expectation of ten analysts for the quarter was for earnings of 32 cents per share. Wall Street expected results to range from -64 cents to $1.92 per share.

Revenue rose 184.4% to $170.64 million from a year ago; analysts expected $50.35 million.

Protagonist Therapeutics Inc's reported EPS for the quarter was $1.98​.

The company reported quarterly net income of $131.67 million.

Protagonist Therapeutics Inc shares had fallen by 6.7% this quarter.

FORECAST CHANGES

The mean earnings estimate of analysts had risen by about 14.1% in the last three months.​

In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Protagonist Therapeutics Inc is $60.00

This summary was machine generated from LSEG data February 25 at 10:01 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Dec. 31 2024
0.32
1.98
Beat
Sep. 30 2024
-0.61
-0.54
Beat
Jun. 30 2024
-0.60
-0.50
Beat
Mar. 31 2024
1.19
3.26
Beat